Publication details

Rituximab je základem léčby Castlemanovy nemoci – multicentrického typu

Title in English Rituximab represents the standard component in the treatment of the multicentric type of Castleman disease
Authors

ADAM Zdeněk POUR Luděk KREJČÍ Marta

Year of publication 2017
Type Article in Periodical
Magazine / Source Postgraduální medicína
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords Castleman disease • rituximab
Description Castleman disease is non-malignant disorder mimicking in its multicentric form malignant lymphoma or multiple myeloma. While unicentric form is usually successfully treated with surgery multicentric form necessitates immunotherapy with rituximab supplemented with chemotherapy when needed. The aim of this short communication is to draw the attention to this relatively rare clinical unit that may represent a diagnostic challenge.

You are running an old browser version. We recommend updating your browser to its latest version.

More info